Find your care

You can trust UCLA Health to deliver an accurate diagnosis and outstanding care using the latest advances in nuclear medicine. Call 310-794-1005 to connect with an expert.

Theranostics provides therapy options for those with prostate cancer, neuroendocrine tumors, thyroid cancer and hyperactive thyroid glands.

The Theranostics process usually involves a diagnostic scan, a consult with a Nuclear Medicine physician and therapy with a radioactive drug.

There are currently four FDA-approved treatments:

  • Lutathera for neuroendocrine tumors
  • Pluvicto and Xofigo for prostate cancer
  •  I-131 for thyroid cancer and hyperactive thyroid glands

Location: Westwood


Drs. Dahlbom, Czernin and Calais.

UCLA Health earns Comprehensive Center of Excellence designation for radiopharmaceutical therapy as work continues on new facility

UCLA Health’s Ahmanson Translational Theranostics Division, part of the Department of Molecular and Medical Pharmacology at the David Geffen School of Medicine at UCLA, has been designated a Comprehensive Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine & Molecular Imaging (SNMMI).